258 related articles for article (PubMed ID: 29102463)
1. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.
Stama ML; Ślusarczyk J; Lacivita E; Kirpotina LN; Schepetkin IA; Chamera K; Riganti C; Perrone R; Quinn MT; Basta-Kaim A; Leopoldo M
Eur J Med Chem; 2017 Dec; 141():703-720. PubMed ID: 29102463
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders.
Mastromarino M; Favia M; Schepetkin IA; Kirpotina LN; Trojan E; Niso M; Carrieri A; Leśkiewicz M; Regulska M; Darida M; Rossignolo F; Fontana S; Quinn MT; Basta-Kaim A; Leopoldo M; Lacivita E
J Med Chem; 2022 Mar; 65(6):5004-5028. PubMed ID: 35257581
[TBL] [Abstract][Full Text] [Related]
3. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
4. Time-Dependent Protective and Pro-Resolving Effects of FPR2 Agonists on Lipopolysaccharide-Exposed Microglia Cells Involve Inhibition of NF-κB and MAPKs Pathways.
Tylek K; Trojan E; Leśkiewicz M; Regulska M; Bryniarska N; Curzytek K; Lacivita E; Leopoldo M; Basta-Kaim A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572022
[TBL] [Abstract][Full Text] [Related]
5. Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.
Stama ML; Lacivita E; Kirpotina LN; Niso M; Perrone R; Schepetkin IA; Quinn MT; Leopoldo M
ChemMedChem; 2017 Nov; 12(22):1839-1847. PubMed ID: 28922577
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation.
Maciuszek M; Ortega-Gomez A; Maas SL; Perretti M; Merritt A; Soehnlein O; Chapman TM
Eur J Med Chem; 2021 Mar; 214():113194. PubMed ID: 33548634
[TBL] [Abstract][Full Text] [Related]
7. Functions of resolvin D1-ALX/FPR2 receptor interaction in the hemoglobin-induced microglial inflammatory response and neuronal injury.
Liu GJ; Tao T; Wang H; Zhou Y; Gao X; Gao YY; Hang CH; Li W
J Neuroinflammation; 2020 Aug; 17(1):239. PubMed ID: 32795323
[TBL] [Abstract][Full Text] [Related]
8. Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
Lacivita E; Schepetkin IA; Stama ML; Kirpotina LN; Colabufo NA; Perrone R; Khlebnikov AI; Quinn MT; Leopoldo M
Bioorg Med Chem; 2015 Jul; 23(14):3913-24. PubMed ID: 25549897
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A
de Gaetano M; Tighe C; Gahan K; Zanetti A; Chen J; Newson J; Cacace A; Marai M; Gaffney A; Brennan E; Kantharidis P; Cooper ME; Leroy X; Perretti M; Gilroy D; Godson C; Guiry PJ
J Med Chem; 2021 Jul; 64(13):9193-9216. PubMed ID: 34138563
[TBL] [Abstract][Full Text] [Related]
10. Microglia Depletion Attenuates the Pro-Resolving Activity of the Formyl Peptide Receptor 2 Agonist AMS21 Related to Inhibition of Inflammasome NLRP3 Signalling Pathway: A Study of Organotypic Hippocampal Cultures.
Tylek K; Trojan E; Leśkiewicz M; Ghafir El Idrissi I; Lacivita E; Leopoldo M; Basta-Kaim A
Cells; 2023 Nov; 12(21):. PubMed ID: 37947648
[TBL] [Abstract][Full Text] [Related]
11. Lipoxin A4 Reduces Inflammation Through Formyl Peptide Receptor 2/p38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats.
Guo Z; Hu Q; Xu L; Guo ZN; Ou Y; He Y; Yin C; Sun X; Tang J; Zhang JH
Stroke; 2016 Feb; 47(2):490-7. PubMed ID: 26732571
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors.
Xu Z; Wu J; Zheng J; Ma H; Zhang H; Zhen X; Zheng LT; Zhang X
Int Immunopharmacol; 2015 Apr; 25(2):528-37. PubMed ID: 25765352
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists.
Maciuszek M; Ortega-Gomez A; Maas SL; Garrido-Mesa J; Ferraro B; Perretti M; Merritt A; Nicolaes GAF; Soehnlein O; Chapman TM
Eur J Med Chem; 2021 Dec; 226():113805. PubMed ID: 34536667
[TBL] [Abstract][Full Text] [Related]
15. RvD1binding with FPR2 attenuates inflammation via Rac1/NOX2 pathway after neonatal hypoxic-ischemic injury in rats.
Liu W; Huang J; Doycheva D; Gamdzyk M; Tang J; Zhang JH
Exp Neurol; 2019 Oct; 320():112982. PubMed ID: 31247196
[TBL] [Abstract][Full Text] [Related]
16. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells.
Cui YH; Le Y; Gong W; Proost P; Van Damme J; Murphy WJ; Wang JM
J Immunol; 2002 Jan; 168(1):434-42. PubMed ID: 11751990
[TBL] [Abstract][Full Text] [Related]
17. The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Exhibits Anti-Inflammatory Activity in LPS-Stimulated Organotypic Hippocampal Cultures.
Trojan E; Tylek K; Leśkiewicz M; Lasoń W; Brandenburg LO; Leopoldo M; Lacivita E; Basta-Kaim A
Cells; 2021 Jun; 10(6):. PubMed ID: 34204273
[TBL] [Abstract][Full Text] [Related]
18. The Lipidated Peptidomimetic Lau-((S)-Aoc)-(Lys-βNphe)6-NH2 Is a Novel Formyl Peptide Receptor 2 Agonist That Activates Both Human and Mouse Neutrophil NADPH Oxidase.
Holdfeldt A; Skovbakke SL; Winther M; Gabl M; Nielsen C; Perez-Gassol I; Larsen CJ; Wang JM; Karlsson A; Dahlgren C; Forsman H; Franzyk H
J Biol Chem; 2016 Sep; 291(38):19888-99. PubMed ID: 27422818
[TBL] [Abstract][Full Text] [Related]
19. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
20. Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation.
Lim HW; Park JI; More SV; Park JY; Kim BW; Jeon SB; Yun YS; Park EJ; Yoon SH; Choi DK
Brain Res Bull; 2015 Mar; 112():25-34. PubMed ID: 25596423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
